Invirase and Splenomegaly - a phase IV clinical study of FDA data

Summary:

Splenomegaly is reported as a side effect among people who take Invirase (saquinavir mesylate), especially for people who are male, 40-49 old, have been taking the drug for 2 - 5 years also take Videx, and have Hiv infection.

The phase IV clinical study analyzes which people have Splenomegaly when taking Invirase. It is created by eHealthMe based on reports of 2,682 people who have side effects when taking Invirase from the FDA, and is updated regularly.

What is Invirase?

Invirase has active ingredients of saquinavir mesylate. eHealthMe is studying from 2,690 Invirase users. Check the latest studies of Invirase.

What is Splenomegaly?

Splenomegaly (enlargement of spleen) is found to be associated with 1,129 drugs and 1,474 conditions by eHealthMe. Check the latest studies of Splenomegaly.

On May, 24, 2026

2,682 people reported to have side effects when taking Invirase.
Among them, 18 people (0.67%) have Splenomegaly.

Among these 18 people:

* Approximation only. Some reports may have incomplete information.

Do you take Invirase and have Splenomegaly?

- Check whether Splenomegaly is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Invirase:

Invirase (2,690 reports)

Splenomegaly treatments and more:

Splenomegaly (17,256 reports)

How severe was Splenomegaly and when was it recovered:

Splenomegaly in Invirase

Expand to all the drugs that have ingredients of saquinavir mesylate:

Splenomegaly and drugs with ingredients of saquinavir mesylate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Invirase:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Splenomegaly:

Splenomegaly (1,129 drugs)

Browse all the conditions that are associated with Splenomegaly:

Splenomegaly (1,474 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on saquinavir mesylate (the active ingredients of Invirase) and Invirase (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.